Mylanpharmaceuticals Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Mylanpharmaceuticals Inc Pharmaceutical Import Records from India — 2 Products, $800.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mylanpharmaceuticals Inc — Pharmaceutical Importer Profile (2026) | 2 Products, $800.0K Trade | TransData Nexus

Mylanpharmaceuticals Inc

Pharmaceutical Importer · United States · Cardiovascular Focus · $800.0K Total Trade · DGFT Verified

Mylanpharmaceuticals Inc is a pharmaceutical importer based in United States with a total trade value of $800.0K across 2 products in 2 therapeutic categories. Based on 16 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Mylanpharmaceuticals Inc sources from 3 verified Indian suppliers, with Mylan Laboratories Limited accounting for 98.6% of imports.

Mylanpharmaceuticals Inc — Import Portfolio & Supplier Network

Mylanpharmaceuticals Inc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Mylanpharmaceuticals Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$5.6M	160	98.6%
Usv Private Limited	$50.0K	1	0.9%
Unichem Laboratories Limited

What Formulations Does Mylanpharmaceuticals Inc Import?

Formulation	Value	Ships
Pantoprazole sodium delayed-release	$473.5K	11
Valsartan and hydrochlorothiazide	$414.1K	9
Potassium chloride extended-release	$391.5K	10
Verapamil hcl extended-release	$302.6K	10
Metformin hydrochloride tablets USP	$300.0K	6
Atorvastatin calcium tablets USP 80 MG	$250.0K	5
Metoprolol succinate extended release	$213.1K	7
Atovaquone and proguanil hydrochloride	$150.0K	3
Fenofibrate tablets USP 145 MG 90bt	$148.9K	3
Lansoprazole delayed release capsules	$135.1K	3
Harmless medicines:- amlodipine and	$134.7K	3
Buspirone hydrochloride tablets USP 15	$119.2K	5
Candesartan cilexetil tablets USP 32 MG	$100.0K	2
Harmless medicines:- atorvastatin calciu	$100.0K	2
Diltiazem hcl extended-release	$86.1K	3

Mylanpharmaceuticals Inc imports 82 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Valsartan	Cardiovascular	$600.0K	12	0.3%	17
2	Proguanil	Antimalarial & Antiparasitic	$200.0K	4	0.0%	6

Mylanpharmaceuticals Inc imports 2 pharmaceutical products across 2 categories into United States totaling $800.0K.

Mylanpharmaceuticals Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Mylanpharmaceuticals Inc is a U.S.-based pharmaceutical importer specializing in the procurement of finished pharmaceutical formulations from international suppliers, particularly from India. The company operates as a buyer within the U.S. pharmaceutical distribution network, focusing on sourcing specific generic medications to meet domestic market demands. While the exact headquarters location is not specified, Mylanpharmaceuticals Inc's activities are integral to the U.S. pharmaceutical supply chain, contributing to the availability of essential generic drugs.

2Distribution Network

Specific details regarding Mylanpharmaceuticals Inc's warehouse locations and logistics capabilities are not publicly disclosed. However, as a pharmaceutical importer, the company likely collaborates with third-party logistics providers to manage the storage and distribution of imported products across the United States. This network ensures that imported medications are efficiently delivered to various stakeholders, including wholesalers, healthcare providers, and pharmacies, thereby supporting the broader U.S. pharmaceutical supply chain.

3Industry Role

Mylanpharmaceuticals Inc functions primarily as a pharmaceutical importer and buyer within the U.S. market. By sourcing finished pharmaceutical formulations from international suppliers, especially from India, the company plays a crucial role in enhancing the availability of generic medications. This activity supports the U.S. healthcare system by providing cost-effective alternatives to brand-name drugs, thereby contributing to the overall efficiency and accessibility of pharmaceutical products.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Mylanpharmaceuticals Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Mylanpharmaceuticals Inc's sourcing strategy exhibits a high degree of concentration, with 100% of its imports comprising two products: Valsartan and Proguanil. Valsartan, a cardiovascular medication, accounts for $600K of the total import value, while Proguanil, an antimalarial, represents $200K. This focused approach suggests a strategic decision to concentrate on specific therapeutic areas, potentially leveraging established supplier relationships and market demand. The stability of this sourcing pattern indicates a reliable supply chain, though it also highlights the company's dependency on a limited number of products and suppliers.

2Supply Chain Resilience

Mylanpharmaceuticals Inc's supply chain resilience is influenced by its reliance on a limited number of suppliers. The primary supplier, Mylan Laboratories Limited, accounts for 98.6% of the total import value, indicating a strong and stable relationship. However, the company's dependence on a single supplier for the majority of its imports could pose risks in the event of supply disruptions. Diversifying the supplier base and incorporating a broader range of formulations could enhance supply chain resilience and mitigate potential vulnerabilities.

3Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which mandates that all drugs imported into the U.S. meet specific standards for quality, safety, and effectiveness. This includes ensuring that imported drugs are not adulterated, misbranded, or unapproved. The FDA's role is critical in maintaining the integrity of the U.S. pharmaceutical supply chain and protecting public health.

2Import Licensing & GMP

Importers of pharmaceutical products into the United States must comply with FDA regulations, which include obtaining appropriate import licenses and ensuring that imported drugs meet Good Manufacturing Practice (GMP) standards. GMP certification, such as EU GMP, WHO GMP, or PIC/S, is recognized by the FDA and is essential for the importation process. Additionally, importers must have wholesale distribution authorization to handle and distribute pharmaceutical products within the U.S. market. These requirements are in place to ensure that imported drugs are safe, effective, and of high quality.

3Quality & Labeling

Mylanpharmaceuticals Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Mylanpharmaceuticals Inc's focus on importing Valsartan and Proguanil aligns with strategic objectives to address specific therapeutic needs within the U.S. market. Valsartan, a medication used to treat high blood pressure and heart failure, and Proguanil, an antimalarial drug, are essential in managing chronic conditions and preventing infectious diseases. The decision to import these products is driven by consistent market demand and the company's commitment to providing cost-effective generic alternatives to brand-name drugs. This strategy supports the broader goal of enhancing access to essential medications for patients across the United States.

2Sourcing Profile

Mylanpharmaceuticals Inc's sourcing strategy is centered on procuring generic drugs from international suppliers, particularly from India, which is a significant global supplier of affordable therapeutics. The company's focus on finished pharmaceutical formulations, rather than active pharmaceutical ingredients (APIs), indicates a preference for ready-to-market products that can be directly distributed within the U.S. market. This approach leverages India's manufacturing capabilities and cost advantages, aligning with the company's objectives to provide high-quality, cost-effective medications to U.S. consumers.

3Market Positioning

Seller's Guide — How to Become a Supplier to Mylanpharmaceuticals Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Mylanpharmaceuticals Inc, particularly in the supply of Valsartan and Proguanil. The company's concentrated sourcing pattern suggests a potential interest in diversifying its supplier base to mitigate risks associated with over-reliance on a single source. Indian exporters can explore this opportunity by ensuring compliance with FDA regulations, maintaining high-quality manufacturing standards, and establishing reliable supply chains. Additionally, offering a broader range of formulations could attract interest from Mylanpharmaceuticals Inc, potentially leading to increased business opportunities.

2Requirements & Qualifications

Indian exporters seeking to supply Mylanpharmaceuticals Inc and the U.S. market must adhere to FDA regulations, including obtaining appropriate import licenses and ensuring that their products meet GMP standards recognized by the FDA, such as EU GMP, WHO GMP, or PIC/S. Additionally, exporters must ensure that their products comply with FDA labeling requirements, including accurate and informative labeling in English. Maintaining high-quality manufacturing practices and establishing a reliable supply chain are essential to meet the FDA's standards and to build trust with U.S. importers.

Frequently Asked Questions — Mylanpharmaceuticals Inc

What products does Mylanpharmaceuticals Inc import from India?

Mylanpharmaceuticals Inc imports 2 pharmaceutical products across 2 categories. Top imports: Valsartan ($600.0K), Proguanil ($200.0K).

Who supplies pharmaceuticals to Mylanpharmaceuticals Inc from India?

Mylanpharmaceuticals Inc sources from 3 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (98.6% of imports, $5.6M).

What is Mylanpharmaceuticals Inc's total pharmaceutical import value?

Mylanpharmaceuticals Inc's total pharmaceutical import value from India is $800.0K, based on 16 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Mylanpharmaceuticals Inc focus on?

Mylanpharmaceuticals Inc imports across 2 categories. The largest: Cardiovascular (75.0%), Antimalarial & Antiparasitic (25.0%).

Get Full Mylanpharmaceuticals Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.